Coordinated Financial Services Inc. bought a new position in Kenvue Inc. (NYSE:KVUE - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 13,798 shares of the company's stock, valued at approximately $295,000.
Several other institutional investors have also modified their holdings of the stock. Concurrent Investment Advisors LLC lifted its holdings in Kenvue by 131.9% in the third quarter. Concurrent Investment Advisors LLC now owns 53,517 shares of the company's stock valued at $1,238,000 after acquiring an additional 30,438 shares during the last quarter. Graypoint LLC acquired a new position in shares of Kenvue in the 3rd quarter valued at $233,000. Principal Financial Group Inc. grew its holdings in shares of Kenvue by 3.2% during the 3rd quarter. Principal Financial Group Inc. now owns 2,364,451 shares of the company's stock worth $54,690,000 after purchasing an additional 73,542 shares during the period. CWA Asset Management Group LLC acquired a new stake in shares of Kenvue during the 3rd quarter worth about $307,000. Finally, Galvin Gaustad & Stein LLC purchased a new stake in Kenvue in the 3rd quarter valued at about $214,000. Hedge funds and other institutional investors own 97.64% of the company's stock.
Kenvue Stock Down 1.3 %
NYSE:KVUE traded down $0.31 during mid-day trading on Tuesday, hitting $23.62. The stock had a trading volume of 6,747,169 shares, compared to its average volume of 14,450,220. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a market capitalization of $45.13 billion, a PE ratio of 44.52, a PEG ratio of 2.62 and a beta of 1.25. The stock has a 50-day simple moving average of $21.69 and a two-hundred day simple moving average of $22.35.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.
Kenvue Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.47%. Kenvue's dividend payout ratio is currently 154.72%.
Analyst Upgrades and Downgrades
KVUE has been the subject of several research analyst reports. Citigroup lowered their target price on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research note on Wednesday, January 15th. Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Barclays lowered their price target on Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. Piper Sandler boosted their price objective on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a report on Monday, February 24th. Finally, UBS Group lowered their target price on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $23.75.
Read Our Latest Stock Analysis on Kenvue
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
